AHAnna R. Huppler

Anna R. Huppler

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anna R. Huppler has a total of 113 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Infection burden in mismatched unrelated donor hematopoietic cell transplantation: results from the ACCESS trial

    by Jeffery J. Auletta, Joseph Stanek, Stephanie Bo-Subait, Monzr M. Al Malki, Rachel Cook, Mahasweta Gooptu, Brian Shaffer, Antonio Jimenez Jimenez, Dipenkumar Modi, Joshua A. Hill, et al.

    HLA-mismatched unrelated donor (MMUD) hematopoietic cell transplantation (HCT) has emerged as an effective therapy for adult patients with hematologic malignancies. The MMUD ACCESS trial, which incorporated posttransplant cyclophosphamide (PTCy) as graft-versus-host disease (GvHD) prophylaxis, demonstrated a combined overall survival of 81% in enrolled patients, 59% of whom were from ethnically diverse groups. Given that PTCy is also associated with significant bacterial and viral infections, we defined infection burden in the full adult cohort (N = 268) using infections graded according to an international standard (Common Terminology Criteria for Adverse Events [CTCAE] version 5.0). Infection density (number of infections per 100 days at risk), cumulative incidence of infection, and frequency of pathogen types were categorized by post-HCT time, conditioning intensity, level of donor HLA mismatch, and presence of acute GvHD (aGvHD). Of 465 CTCAE grade 2 to 5 infections recorded in 183 (68%) adults, 176 (38%) were significant or life-threatening, and most (296 [64%]) occurred within the first 100 days. Infection density at days 0 to 30 was significantly higher than at other times and was similar by conditioning and level of HLA mismatch, as were pathogen types and isolates. Multivariable analysis showed that aGvHD is significantly associated with infection. Finally, 21 (7.8%) patients died of infection. Results show significant infection burden using standard-dose PTCy in the MMUD HCT setting, irrespective of conditioning and level of donor HLA mismatch, and serve as a benchmark for trials investigating reducing infection burden after MMUD HCT. This trial was registered at www.clinicaltrials.gov as NCT04904588.


  • Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis

    by Kitsada Wudhikarn, Lohith Gowda, Qiran Ye, Temitope Oloyede, Michael Martens, Rahul Banerjee, Srinivas S. Devarakonda, Hongtao Liu, Megan M. Herr, Jo-Anne H. Young, et al.

  • Open Access

    Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis

    by Hemalatha G. Rangarajan, Prakash Satwani, Megan M. Herr, Min Chen, Michael J. Martens, Kitsada Wudhikarn, Samuel John, Vanessa A. Fabrizio, Emily M. Hsieh, Amar H. Kelkar, et al.

    Tisagenlecleucel (tisa-cel) is a CD19-directed chimeric antigen receptor T-cell therapy for relapsed/refractory precursor B-cell acute lymphoblastic leukemia (R/R B-ALL). We report infectious complications for 100 days (D100) following tisa-cel therapy in 471 pediatric and young adults (median age 13.8 years) with R/R B-ALL reported from September 2017 to June 2022. By D100, 137 (29%) patients had an infectious event, with an infection density of 0.542 per 100 person-days at risk. D100 cumulative incidences of bacterial, viral, and fungal infections were 14.1%, 11.6%, and 1.3%, corresponding to infection density scores of 0.296, 0.213, and 0.033 per 100 person-days at risk, respectively. In a multivariable analysis, receipt of ≥3 lines of therapy before tisa-cel (hazard ratio [HR], 1.86; 95% confidence interval [CI], 1.13-3.08; P = .015), any-grade cytokine release syndrome (HR, 1.78; 95% CI, 1.17-2.71; P = .007), and lack of neutrophil recovery (HR, 2.63; 95% CI, 1.47-4.69; P = .001) were associated with an increased risk for any infection. Similar associations were observed for bacterial infections, with the addition of younger age as an adverse risk (<6 vs 6-15 years; HR, 2.38; 95% CI, 1.23-4.61; P = .01). Risk factors for viral infections included increasing age (1-year increase; HR, 1.05; 95% CI, 1.01-1.09; P = .016), prior history of any infection (HR, 2.76, 95% CI, 1.40-5.46; P = .004), and prior hematopoietic cell transplant (HR, 2.10; 95% CI, 1.18-3.71; P = .011). D100 infection-related mortality (IRM) rate was low at 0.2% (95% CI, 0.0-0.8). In this multicenter real-world study, we observed a high incidence of infectious complications but a low IRM following tisa-cel for R/R B-ALL.


  • Open Access

    Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR

    by Kitsada Wudhikarn, Megan M. Herr, Min Chen, Michael J. Martens, John H. Baird, Lohith Gowda, Hemalatha G. Rangarajan, Muhammad Bilal Abid, Mohamed A. Kharfan-Dabaja, Kirsten M. Williams, et al.

    Infection is increasingly recognized as a significant cause of morbidity and mortality in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) receiving CD19 chimeric antigen receptor (CAR) T-cell therapy. The current study analyzed the natural history, risk factors, and outcomes of infection in 3350 patients with R/R LBCL receiving commercial CD19 CAR T-cell therapy (n = 2804 axicabtagene ciloleucel [axi-cel], n = 546 tisagenlecleucel) from December 2017 to June 2022. Infection developed in 834 patients (24.9%) within 100 days after infusion, resulting in an infection density of 0.43 per 100 patient days and a 100-day cumulative incidence of 22%. Bacterial, viral, and fungal infections were recorded in 527 (15.7%), 374 (11.2%), and 108 patients (3.2%), respectively, with corresponding infection densities of 0.23, 0.15, and 0.04 per 100 patient days. After a 24-month median follow-up, 1482 patients (44%) had died, with infection as the primary cause in 173 cases (12%). The 100-day infection-related mortality (IRM) was 1.6% (95% confidence interval, 1.2-2.0). Patients with a Karnofsky performance score of ≤80, infection history before CAR T-cell therapy, axi-cel therapy, severe cytokine release syndrome (grade ≥3), and severe immune effector cell–associated neurotoxicity syndrome (grade ≥3) had increased infection risk. Infections within 100 days were an independent risk factor for inferior overall survival beyond day 100 after CD19 CAR T-cell therapy. In conclusion, study results show a significant incidence of infection and IRM in patients with R/R LBCL treated with CD19 CAR T-cell therapy. Furthermore, results identify patients at a heightened risk of infection, offering insights to guide potential interventions aimed at mitigating infection and improving patient outcomes after CAR T-cell therapy.


  • Top Cited Papers
    Open Access

    Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy – A Report from the CIBMTR

    by Stephen R. Spellman, Ke Xu, Temitope Oloyede, Kwang Woo Ahn, Othman Akhtar, Yung-Tsi Bolon, Larisa Broglie, Jenni Bloomquist, Caitrin Bupp, Min Chen, et al.


  • An Optimized Voriconazole Dosing Strategy to Achieve Therapeutic Serum Concentrations in Children Younger than 2 Years Old

    by Tracy N. Zembles, Nathan E. Thompson, Peter L. Havens, Bruce A. Kaufman, Anna R. Huppler

    Study Objective: To describe our experience with voriconazole in three patients younger than 2 years using an optimized dosing strategy for voriconazole that incorporates intensive therapeutic drug monitoring (TDM).Design: Case series.Setting: Large pediatric hospital.Patients: Three patients younger than 2 years who received voriconazole therapy and had serum trough concentrations measured between January 1, 2010, and October 31, 2015.Measurements and Main Results: A clinical practice guideline developed at our institution was used to standardize initial dosing, appropriate use and timing of TDM, and dosage modifications based on TDM. TDM was used to guide dosing to achieve a target voriconazole serum trough concentration of 2–6 μg/ml. Voriconazole samples were assayed by using a high‐performance liquid chromatography analytical method with solid‐phase extraction. Initial dosages for the three patients were 9 mg/kg intravenously every 12 hours (one patient) and 9 mg/kg enterally twice/day (two patients). Multiple dose escalations and a more frequent dosing interval were required to achieve trough concentrations within the target range. The final dosages were 12 mg/kg intravenously every 8 hours, 17.7 mg/kg enterally 3 times/day, and 8.5 mg/kg enterally 3 times/day, respectively. In addition to voriconazole trough concentrations, TDM included evaluations for drug toxicities. Visual, neurologic, or hepatic adverse effects were not encountered in the three patients.Conclusion: Our data support higher initial doses and perhaps a 3 times/day dosing schedule to achieve voriconazole serum concentrations in the target range for children younger than 2 years. Implementation of a clinical practice guideline with the participation of pharmacists specializing in pharmacokinetics allows for effective use of voriconazole in young children.


  • Editorial: Fake it ’til you make it: mast cells acquire IL-17 exogenously

    by Anna R. Huppler, Sarah L. Gaffen

    Discussion of how mast cells can acquire IL-17 through cellular uptake.